Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021)
Taysha Gene Therapies' (TSHA) quarterly Long-Term Debt Issuances came in at $10.0 million in Q4 2021, up 497.73% quarter-over-quarter from $1.7 million in Q1 2020.
Taysha Gene Therapies (TSHA) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Taysha Gene Therapies has disclosed Long-Term Debt Issuances across 2 years of filings, most recently posting $10.0 million for Q4 2021.
- Long-Term Debt Issuances for Q4 2021 came in at $10.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $10.0 million (up 497.73% YoY), and the FY2021 annual result was $10.0 million, up 497.73% from the prior year.
- Long-Term Debt Issuances came in at $10.0 million for Q4 2021 at Taysha Gene Therapies, up from $1.7 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $10.0 million in Q4 2021 to a low of $1.7 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Mar 31, 2020 | 1.67 Mn |
| Mar 31, 2020 | 1.67 Mn |